Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurocrine (NBIX)
NASDAQ:NBIX
Holding NBIX?
Track your performance easily
NBIX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$110.95 - $157.98
Previous Close$126.42
Volume548.45K
Average Volume (3M)916.25K
Market Cap
$12.93B
Enterprise Value$11.96B
Total Cash (Recent Filing)$1.23B
Total Debt (Recent Filing)$251.40M
Price to Earnings (P/E)33.9
Beta0.59
Next Earnings
Feb 11, 2025EPS Estimate
$1.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.73
Shares Outstanding101,246,911
10 Day Avg. Volume868,993
30 Day Avg. Volume916,245
Standard Deviation0.08
R-Squared0.05
Alpha0.00050
Financial Highlights & Ratios
Price to Book (P/B)4.71
Price to Sales (P/S)5.77
Price to Cash Flow (P/CF)20.50
P/FCF Ratio21.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.33
Enterprise Value/Gross Profit6.47
Enterprise Value/Ebitda21.48
Forecast
1Y Price Target
$166.53Price Target Upside29.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Neurocrine News
PremiumCompany Announcements
Neurocrine Biosciences Reports Strong Q3 2024 Earnings
Bulls Say, Bears Say
Bulls Say
Market PresenceA significant portion of patients, 80%, continue to have access to Ingrezza, demonstrating its strong market presence.
Pipeline AdvancementsThe emraclidine setback leaves Neurocrine with the most advanced and the broadest pipeline of muscarinics behind Karuna/Bristol Myers Squibb.
Product GrowthManagement raised its 2024 sales outlook for Ingrezza again, which is viewed as a sign of continued solid execution on the product.
Bears Say
Clinical Trial OutcomesEmraclidine's high profile failure likely raises concerns over the role of M4 selectivity vs. broader targeting.
Earnings PerformanceGAAP EPS of $1.24 was approximately 18% below the consensus of $1.52, reflecting a shortfall in earnings.
Pipeline And DevelopmentNeurocrine disclosed that the phase 2 ERUDITE study of luvadaxistat failed to meet the primary endpoint in the setting of cognitive impairment in patients with schizophrenia (CIS), and are discontinuing further development.
---
Ownership Overview
1.04% Insiders
22.96% Mutual Funds
23.97% Other Institutional Investors
22.95% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NBIX FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $110.95 and its highest was $157.98 in the past 12 months.
What is Neurocrine’s market cap?
Currently, no data Available
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is Feb 11, 2025 which is in 66 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on Oct 30, 2024. The company reported $1.24 earnings per share for the quarter, missing the consensus estimate of $1.517 by -$0.277.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is $1.61.
How many shares outstanding does Neurocrine have?
Neurocrine has 101,246,910 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $1.24 in its last earnings report, missing expectations of $1.517. Following the earnings report the stock price went up 7.006%.
Which hedge fund is a major shareholder of Neurocrine?
Among the largest hedge funds holding Neurocrine’s share is Deerfield Management Company, LP. It holds Neurocrine’s shares valued at 152M.
---
Neurocrine Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$166.53 (29.96% Upside)
$166.53 (29.96% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 66.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.64%
12-Months-Change
Fundamentals
Return on Equity
16.35%
Trailing 12-Months
Asset Growth
24.11%
Trailing 12-Months
Company Description
Neurocrine
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.
---
NBIX Company Deck
---
NBIX Earnings Call
Q3 2024
0:00 / 0:00
---
NBIX Stock 12 Month Forecast
Average Price Target
$166.53
▲(29.96% Upside)
Technical Analysis
Best Analysts Covering NBIX
1 Year
1 Year Success Rate
16/24 ratings generated profit
1 Year Average Return
+8.61%
reiterated a buy rating last month
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +8.61% per trade.
---